10.50
price down icon0.66%   -0.07
after-market アフターアワーズ: 10.43 -0.07 -0.67%
loading
前日終値:
$10.57
開ける:
$10.67
24時間の取引高:
96,202
Relative Volume:
1.04
時価総額:
$336.79M
収益:
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.2108
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
-27.29%
6か月 パフォーマンス:
-51.61%
1年 パフォーマンス:
-43.24%
1日の値動き範囲:
Value
$10.19
$10.67
1週間の範囲:
Value
$10.19
$13.07
52週間の値動き範囲:
Value
$8.85
$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
名前
Cartesian Therapeutics Inc
Name
セクター
Healthcare (1151)
Name
電話
301-348-8698
Name
住所
7495 NEW HORIZON WAY, FREDERICK
Name
職員
66
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
RNAC's Discussions on Twitter

RNAC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNAC
Cartesian Therapeutics Inc
10.50 336.79M 26.00M -219.71M -51.37M -49.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-19 開始されました BTIG Research Buy
2024-08-06 開始されました TD Cowen Buy
2024-07-02 ダウングレード Oppenheimer Outperform → Perform
2024-06-04 開始されました Oppenheimer Outperform
2024-05-24 開始されました Mizuho Buy
2024-04-23 繰り返されました H.C. Wainwright Buy
2024-04-23 開始されました Leerink Partners Outperform
2023-08-18 ダウングレード SVB Securities Outperform → Market Perform
2022-06-14 繰り返されました Needham Buy
2022-06-06 開始されました SVB Leerink Outperform
2021-06-15 開始されました BTIG Research Buy
2021-01-26 アップグレード Mizuho Neutral → Buy
2020-10-01 ダウングレード Mizuho Buy → Neutral
2020-10-01 ダウングレード William Blair Outperform → Mkt Perform
2020-06-12 ダウングレード Stifel Buy → Hold
2020-04-28 開始されました H.C. Wainwright Buy
2020-01-29 開始されました Cantor Fitzgerald Overweight
2020-01-21 開始されました William Blair Outperform
2018-06-27 開始されました Janney Buy
2017-03-30 繰り返されました UBS Buy
すべてを表示

Cartesian Therapeutics Inc (RNAC) 最新ニュース

pulisher
Apr 18, 2025

Cartesian Therapeutics (RNAC) Stock Gains Momentum In After-Hour Trading - Stocks Telegraph

Apr 18, 2025
pulisher
Apr 16, 2025

Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Apr 16, 2025
pulisher
Apr 12, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock - Investing.com Australia

Apr 11, 2025
pulisher
Apr 11, 2025

Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 09, 2025

Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter

Apr 09, 2025
pulisher
Apr 09, 2025

US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech

Apr 08, 2025
pulisher
Apr 08, 2025

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com

Apr 08, 2025
pulisher
Apr 08, 2025

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga

Apr 08, 2025
pulisher
Apr 08, 2025

Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan

Apr 08, 2025
pulisher
Apr 03, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Apr 01, 2025
pulisher
Mar 29, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World

Mar 29, 2025
pulisher
Mar 23, 2025

Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo

Mar 23, 2025
pulisher
Mar 21, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st

Mar 18, 2025
pulisher
Mar 17, 2025

Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada

Mar 17, 2025
pulisher
Mar 16, 2025

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st

Mar 15, 2025
pulisher
Mar 15, 2025

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Cartesian Therapeutics Inc. (RNAC) reports earnings - Quartz

Mar 13, 2025
pulisher
Mar 13, 2025

Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Cartesian Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Cartesian's $214M War Chest Powers Breakthrough Myasthenia Gravis Treatment into Phase 3 - StockTitan

Mar 13, 2025
pulisher
Mar 11, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Target Price from Analysts - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

New York State Common Retirement Fund Sells 1,200 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Inside Cartesian's Latest Executive Compensation Package: Key Details Revealed - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

Cartesian Therapeutics Advances Descartes-08 in Clinical Trials - TipRanks

Mar 03, 2025
pulisher
Feb 27, 2025

Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 18, 2025

Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 18, 2025

Cartesian Therapeutics Inc (RNAC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):